7th International Immunoglobulin Conference: Immunodeficiencies

被引:1
作者
Schmidt, R. E. [1 ]
Ochs, H. D. [2 ,3 ]
机构
[1] Hannover Med Sch, Hannover, Germany
[2] Univ Washington, Seattle, WA 98195 USA
[3] Seattle Childrens Res Inst, Seattle, WA USA
关键词
diagnosis; immunodeficiency; intravenous immunoglobulin; subcutaneous immunoglobulin; HYPOGAMMAGLOBULINEMIA; INFECTIONS;
D O I
10.1111/cei.12490
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Most primary immunodeficiency disorders (PID) are the result of single gene defects. Based on this fact, more than 240 different entities have been identified. Those PIDs with predominant antibody deficiency are treated with immunoglobulin (Ig) replacement therapy. This review focuses on the diagnosis, clinical characteristics and treatment of patients suffering from PID, or secondary immunodeficiency disorders (SID) caused, for instance, by irradiation, immunosuppressive drugs or thymectomy. Common variable immunodeficiency (CVID) is the most commonly diagnosed and least understood form of PID, with a heterogeneous range of symptoms and genotypes, requiring individualized treatment plans. This includes adjusting the dose and treatment interval, administrating Ig by intravenous or subcutaneous injection by either pump or push, and finally deciding which treatment options are best for a given patient. Ig therapy can also be used to treat immunodeficiencies resulting from lymphoproliferative and autoimmune diseases or immunosuppression following organ transplantation; however, there is an urgent need for research in this field. Accurate and early diagnosis of PID is important to ensure that optimal treatment is started early to maintain the patient's health. Detailed patient registries have been established to increase awareness of PID, as well as provide a valuable resource for further research.
引用
收藏
页码:3 / 4
页数:2
相关论文
共 50 条
[21]   Immunoglobulin replacement therapy in patients with primary and secondary immunodeficiencies: impact of infusion method on immunoglobulin-specific perceptions of quality of life and treatment satisfaction [J].
Mallick, Rajiv ;
Hahn, Noemi ;
Scalchunes, Christopher .
ALLERGY ASTHMA AND CLINICAL IMMUNOLOGY, 2025, 21 (01)
[22]   A 10% liquid immunoglobulin preparation for intravenous use (Privigen®) in paediatric patients with primary immunodeficiencies and hypersensitivity to IVIG [J].
Lozano-Blasco, J. ;
Martin-Mateos, M. A. ;
Alsina, L. ;
Dominguez, O. ;
Giner, M. T. ;
Piquer, M. ;
Alvaro, M. ;
Plaza, A. M. .
ALLERGOLOGIA ET IMMUNOPATHOLOGIA, 2014, 42 (02) :136-141
[23]   Humoral immunodeficiencies: conferred risk of infections and benefits of immunoglobulin replacement therapy [J].
Gernez, Yael ;
Baker, Mary Grace ;
Maglione, Paul J. .
TRANSFUSION, 2018, 58 :3056-3064
[24]   Efficacy and safety of home-based subcutaneous immunoglobulin replacement therapy in paediatric patients with primary immunodeficiencies [J].
Borte, M. ;
Bernatowska, E. ;
Ochs, H. D. ;
Roifman, C. M. .
CLINICAL AND EXPERIMENTAL IMMUNOLOGY, 2011, 164 (03) :357-364
[25]   Manual Administration of Subcutaneous Immunoglobulin 20% in Clinical Practice in Patients with Immunodeficiencies [J].
Keith, Paul ;
Cowan, Juthaporn ;
Kanani, Amin ;
Kim, Harold ;
Lacuesta, Gina ;
Lee, Jason ;
Chen, Jie ;
Park, Michelle ;
Gladiator, Andre .
JOURNAL OF CLINICAL IMMUNOLOGY, 2022, 42 (SUPPL 1) :S72-S74
[26]   Advances in Nasopharyngeal Carcinoma Staging: from the 7th to the 9th Edition of the TNM System and Future Outlook [J].
Wu, Binhao ;
Chen, Xiaozhong ;
Cao, Caineng .
CURRENT ONCOLOGY REPORTS, 2025, 27 (03) :322-332
[27]   Report on the 6th Ottawa International Conference on Neuromuscular Disease & Biology - September 7-9, 2023, Ottawa, Canada [J].
Warman-Chardon, Jodi ;
Jasmin, Bernard J. ;
Kothary, Rashmi ;
Parks, Robin J. .
JOURNAL OF NEUROMUSCULAR DISEASES, 2025, 12 (01) :102-115
[28]   Differences in 7th and 8th edition American Joint Committee on Cancer staging for periocular sebaceous carcinoma [J].
Reynolds, Roisin R. ;
Davies, Michael J. ;
Buffam, Frank, V ;
Dolman, Peter J. ;
White, Valerie A. .
CANADIAN JOURNAL OF OPHTHALMOLOGY-JOURNAL CANADIEN D OPHTALMOLOGIE, 2021, 56 (01) :31-36
[29]   Medium-to-Long-Term Safety, Efficacy, and Tolerability of Subcutaneous Human Immunoglobulin 16.5% in Patients with Primary Immunodeficiencies [J].
Rizvi, Syed ;
Gupta, Sudhir ;
Kobayashi, Roger ;
Kobayashi, Ai Lan ;
Melamed, Isaac ;
Mandujano, Jose Fernando ;
Geng, Bob ;
Rehman, Syed ;
Ritchie, Bruce ;
Young, Shardae .
JOURNAL OF CLINICAL IMMUNOLOGY, 2021, 41 (SUPPL 1) :S101-S101
[30]   Clinical Efficacy, Safety and Tolerability of a New Subcutaneous Immunoglobulin 16.5% (Octanorm [Cutaquig®]) in the Treatment of Patients With Primary Immunodeficiencies [J].
Kobayashi, Roger H. ;
Gupta, Sudhir ;
Melamed, Isaac ;
Mandujano, J. Fernando ;
Kobayashi, Ai Lan ;
Ritchie, Bruce ;
Geng, Bob ;
Atkinson, Thomas Prescott ;
Rehman, Syed ;
Turpel-Kantor, Eva ;
Litzman, Jiri .
FRONTIERS IN IMMUNOLOGY, 2019, 10